“Our antitrust laws serve important purposes, but federal regulators should not interfere with productive market forces absent evidence demonstrating a significant threat to consumer welfare.  Based on the evidence presented at our Antitrust Subcommittee hearing, I am convinced that although significant in size this merger does not pose a threat to robust competition.  I am pleased that the FTC’s extensive investigation corroborated my view and demonstrated that this transaction is unlikely to have adverse affects on the PBM and specialty drug markets or lead to the exercise of monopsony power over retail pharmacies, and that the merger may well lead to lower prices for PBM services.”